Thus, the best strategy may be to use inhibitors with a more narrow resistance profile (e.g., gilteritinib) or applying combination therapy with chemotherapeutic agents, HSCT, MEK inhibitors, hypo‐methylating agents (HMA), or CDK6 inhibitors to maximize the survival benefit for AML patients.171, 178, 179, 180, 181, 182, 183, 184. Here, CDK6 is linked to acute myeloid leukemia.